Biogen Gross Profit 2010-2022 | BIIB
Biogen annual/quarterly gross profit history and growth rate from 2010 to 2022. Gross profit can be defined as the profit a company makes after deducting the variable costs directly associated with making and selling its products or providing its services.
- Biogen gross profit for the quarter ending June 30, 2022 was $2.105B, a 9.08% decline year-over-year.
- Biogen gross profit for the twelve months ending June 30, 2022 was $8.224B, a 16.26% decline year-over-year.
- Biogen annual gross profit for 2021 was $8.872B, a 23.78% decline from 2020.
- Biogen annual gross profit for 2020 was $11.639B, a 6.3% decline from 2019.
- Biogen annual gross profit for 2019 was $12.423B, a 6.75% increase from 2018.
Biogen Annual Gross Profit
(Millions of US $) |
| 2021 |
$8,872 |
| 2020 |
$11,639 |
| 2019 |
$12,423 |
| 2018 |
$11,637 |
| 2017 |
$10,644 |
| 2016 |
$9,970 |
| 2015 |
$9,523 |
| 2014 |
$8,532 |
| 2013 |
$6,075 |
| 2012 |
$4,971 |
| 2011 |
$4,582 |
| 2010 |
$4,316 |
| 2009 |
$3,995 |
Biogen Quarterly Gross Profit
(Millions of US $) |
| 2022-06-30 |
$2,105 |
| 2022-03-31 |
$1,778 |
| 2021-12-31 |
$2,074 |
| 2021-09-30 |
$2,267 |
| 2021-06-30 |
$2,315 |
| 2021-03-31 |
$2,216 |
| 2020-12-31 |
$2,362 |
| 2020-09-30 |
$2,927 |
| 2020-06-30 |
$3,271 |
| 2020-03-31 |
$3,080 |
| 2019-12-31 |
$3,224 |
| 2019-09-30 |
$3,170 |
| 2019-06-30 |
$3,140 |
| 2019-03-31 |
$2,888 |
| 2018-12-31 |
$3,038 |
| 2018-09-30 |
$2,978 |
| 2018-06-30 |
$2,936 |
| 2018-03-31 |
$2,685 |
| 2017-12-31 |
$2,798 |
| 2017-09-30 |
$2,708 |
| 2017-06-30 |
$2,712 |
| 2017-03-31 |
$2,426 |
| 2016-12-31 |
$2,494 |
| 2016-09-30 |
$2,539 |
| 2016-06-30 |
$2,524 |
| 2016-03-31 |
$2,414 |
| 2015-12-31 |
$2,507 |
| 2015-09-30 |
$2,468 |
| 2015-06-30 |
$2,306 |
| 2015-03-31 |
$2,243 |
| 2014-12-31 |
$2,343 |
| 2014-09-30 |
$2,209 |
| 2014-06-30 |
$2,130 |
| 2014-03-31 |
$1,851 |
| 2013-12-31 |
$1,707 |
| 2013-09-30 |
$1,593 |
| 2013-06-30 |
$1,493 |
| 2013-03-31 |
$1,281 |
| 2012-12-31 |
$1,284 |
| 2012-09-30 |
$1,246 |
| 2012-06-30 |
$1,282 |
| 2012-03-31 |
$1,159 |
| 2011-12-31 |
$1,187 |
| 2011-09-30 |
$1,186 |
| 2011-06-30 |
$1,108 |
| 2011-03-31 |
$1,100 |
| 2010-12-31 |
$1,119 |
| 2010-09-30 |
$1,080 |
| 2010-06-30 |
$1,106 |
| 2010-03-31 |
$1,012 |
| 2009-12-31 |
$1,027 |
| 2009-09-30 |
$1,027 |
| 2009-06-30 |
$1,003 |
| 2009-03-31 |
$938 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$32.069B |
$10.982B |
|
Biogen Inc. is one of the world's leading biotechnology companies which focuses on developing innovative therapies for treating serious neurological and neurodegenerative diseases, including its core growth areas of multiple sclerosis (MS) and neuroimmunology, Alzheimer's disease (AD) and dementia, movement disorders including Parkinson's disease, neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS) and ophthalmology. Key multiple sclerosis/MS drugs in its portfolio are Tecfidera, Vumerity, Avonex, Plegridy, Fampyra and Tysabri. Other approved/marketed products include Fumaderm (severe psoriasis), Spinraza (spinal muscular atrophy (SMA)) and Aduhelm (Alzheimer's disease).
|
